Skip to main content

New Products

  • L'Oréal USA launches connected TV app

    NEW YORK — L'Oréal USA has introduced a new app for owners of a device that allows them to use tablet-like apps on television through an Internet connection.

    The cosmetics maker announced the launch of OnBeauty, which it created under a partnership with Roku and Brightline. Roku created the app for users of connected TV, or CTV, and L'Oréal said OnBeauty would be the go-to beauty hub for CTV users. The app will feature a majority of L'Oréal USA's brands.

  • Olay introduces White Radiance Intensive Fairness Serum, Intensive Fairness Cream

    DUBAI, United Arab Emirates — Procter & Gamble's Olay unit has introduced two new additions to its White Radiance collection of products, the company said.

    The two products, Intensive Fairness Serum and Intensive Fairness Cream, use cellular-level technology and also contain a ultraviolet light blocker with an increased SPF 50 formula.

  • Amneal launches new GERD treatment

    BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.

    Amneal announced Tuesday the launch of esomeprazole strontium delayed-release capsules in the 49.3-mg strength, which it is marketing in the United States under a contract with Hanmi Pharmaceutical Co. The drug is expected to begin shipping Wednesday in 30-count bottles.

  • Greenstone launches authorized generic voriconazole for oral suspension

    PEAPACK, N.J. — Greenstone has launched a version of a drug used to treat fungal infections, the company said.

    Greenstone, the generics subsidiary of Pfizer, announced the introduction of voriconazole for oral suspension, an authorized generic version of Pfizer's Vfend. Authorized generics are branded drugs sold at a discount under their generic names.

    Greenstone is selling the drug in the 40 mg-per-milliliter strength. Vfend had sales of about $17.1 million during the 12-month period that ended in June, according to IMS Health.

     

  • Mylan, Banner settle cancer drug lawsuit with Eisai, Valeant

    PITTSBURGH — Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.

    Mylan said that it and Banner Pharmacaps had reached a settlement agreement with Eisai and a subsidiary of Valeant Pharmaceuticals International to resolve a lawsuit filed over their generic version of Targretin (bexarotene) capsules in the 75-mg strength. The drug is used to treat certain forms of T-cell lymphoma.

  • Endo acquires NuPathe for $105 million

    MALVERN, Pa. – Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.

    Endo said Monday that it would buy NuPathe for $105 million. In January, the FDA approved NuPathe's patch, Zecuity, a disposable, single-use, battery-powered transdermal patch that delivers the drug sumatriptan, the most widely prescribed migraine medication.

  • EMD Serono releases redesigned injector pen for infertility

    ROCKLAND, Mass. — A redesigned version of an injector pen used to treat infertility is available for distribution in the United States, the manufacturer said Monday.

    EMD Serono, a subsidiary of German drug maker Merck KGaA, said that Gonal-f RFF Redi-ject, a disposable, pre-filled pen used for the drug Gonal-f RFF (follitropin alfa), had become available. The Food and Drug Administration approved the redesigned pen in October. Merck KGaA operates in the United States under the name EMD in order to avoid confusion with U.S.-based Merck & Co.

X
This ad will auto-close in 10 seconds